Nesiritide in acute decompensated heart failure

Current status and future perspectives

Selma F. Mohammed, Josef Korinek, Horng Haur Chen, John C Jr. Burnett, Margaret May Redfield

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Acute decompensated heart failure (ADHF) is a growing public health problem with high mortality and costs. ADHF often, if not usually, occurs in the setting of cardiovascular and noncardiovascular comorbidities as well as advanced age. New insights provide support for the concept of heart failure as a state of deficiency of and/or resistance to endogenous B-type natriuretic peptide. The primary goals of ADHF therapy are to relieve symptoms and optimize volume status with minimal side effects. Few therapies are proven to effectively do so. Nesiritide is a balanced vasodilator with favorable neurohumoral effects and is superior to placebo in providing rapid symptom relief and to nitroglycerin in reducing filling pressures. Recent trials confirm a lack of renal toxicity at recommended doses. An adequately powered multinational mortality trial is underway. Nesiritide represents a proven therapy for normotensive/hypertensive ADHF patients with severe symptoms at rest.

Original languageEnglish (US)
Pages (from-to)151-158
Number of pages8
JournalReviews in Cardiovascular Medicine
Volume9
Issue number3
StatePublished - Jun 2008

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Mortality
Nitroglycerin
Vasodilator Agents
Comorbidity
Therapeutics
Public Health
Placebos
Kidney
Pressure
Costs and Cost Analysis

Keywords

  • Acute decompensated heart failure
  • B-type natriuretic peptide
  • Nesiritide
  • Renal function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nesiritide in acute decompensated heart failure : Current status and future perspectives. / Mohammed, Selma F.; Korinek, Josef; Chen, Horng Haur; Burnett, John C Jr.; Redfield, Margaret May.

In: Reviews in Cardiovascular Medicine, Vol. 9, No. 3, 06.2008, p. 151-158.

Research output: Contribution to journalArticle

@article{cac8c7fecc8c4b03b6adb185ea1a5aa5,
title = "Nesiritide in acute decompensated heart failure: Current status and future perspectives",
abstract = "Acute decompensated heart failure (ADHF) is a growing public health problem with high mortality and costs. ADHF often, if not usually, occurs in the setting of cardiovascular and noncardiovascular comorbidities as well as advanced age. New insights provide support for the concept of heart failure as a state of deficiency of and/or resistance to endogenous B-type natriuretic peptide. The primary goals of ADHF therapy are to relieve symptoms and optimize volume status with minimal side effects. Few therapies are proven to effectively do so. Nesiritide is a balanced vasodilator with favorable neurohumoral effects and is superior to placebo in providing rapid symptom relief and to nitroglycerin in reducing filling pressures. Recent trials confirm a lack of renal toxicity at recommended doses. An adequately powered multinational mortality trial is underway. Nesiritide represents a proven therapy for normotensive/hypertensive ADHF patients with severe symptoms at rest.",
keywords = "Acute decompensated heart failure, B-type natriuretic peptide, Nesiritide, Renal function",
author = "Mohammed, {Selma F.} and Josef Korinek and Chen, {Horng Haur} and Burnett, {John C Jr.} and Redfield, {Margaret May}",
year = "2008",
month = "6",
language = "English (US)",
volume = "9",
pages = "151--158",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "3",

}

TY - JOUR

T1 - Nesiritide in acute decompensated heart failure

T2 - Current status and future perspectives

AU - Mohammed, Selma F.

AU - Korinek, Josef

AU - Chen, Horng Haur

AU - Burnett, John C Jr.

AU - Redfield, Margaret May

PY - 2008/6

Y1 - 2008/6

N2 - Acute decompensated heart failure (ADHF) is a growing public health problem with high mortality and costs. ADHF often, if not usually, occurs in the setting of cardiovascular and noncardiovascular comorbidities as well as advanced age. New insights provide support for the concept of heart failure as a state of deficiency of and/or resistance to endogenous B-type natriuretic peptide. The primary goals of ADHF therapy are to relieve symptoms and optimize volume status with minimal side effects. Few therapies are proven to effectively do so. Nesiritide is a balanced vasodilator with favorable neurohumoral effects and is superior to placebo in providing rapid symptom relief and to nitroglycerin in reducing filling pressures. Recent trials confirm a lack of renal toxicity at recommended doses. An adequately powered multinational mortality trial is underway. Nesiritide represents a proven therapy for normotensive/hypertensive ADHF patients with severe symptoms at rest.

AB - Acute decompensated heart failure (ADHF) is a growing public health problem with high mortality and costs. ADHF often, if not usually, occurs in the setting of cardiovascular and noncardiovascular comorbidities as well as advanced age. New insights provide support for the concept of heart failure as a state of deficiency of and/or resistance to endogenous B-type natriuretic peptide. The primary goals of ADHF therapy are to relieve symptoms and optimize volume status with minimal side effects. Few therapies are proven to effectively do so. Nesiritide is a balanced vasodilator with favorable neurohumoral effects and is superior to placebo in providing rapid symptom relief and to nitroglycerin in reducing filling pressures. Recent trials confirm a lack of renal toxicity at recommended doses. An adequately powered multinational mortality trial is underway. Nesiritide represents a proven therapy for normotensive/hypertensive ADHF patients with severe symptoms at rest.

KW - Acute decompensated heart failure

KW - B-type natriuretic peptide

KW - Nesiritide

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=53949088681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53949088681&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 151

EP - 158

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - 3

ER -